Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of INP104 vs IV DHE and Migranal in Healthy Adults
NCT03401346Phase 1Completed
- Sponsor
- Impel Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroergotamine in migraine (3 arms), sponsored by Impel Pharmaceuticals. Primary endpoint: DHE pharmacokinetics at 48 hours. Started Oct 2017; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03401346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401346.